Key points are not available for this paper at this time.
Amid rising competition, Teva Pharmaceutical Industries intends to divest its active pharmaceutical ingredients (API) unit to focus on other businesses, including in-house drug development. In 2023, the 4, 300-employee unit, a provider of small-molecule APIs, recorded sales of 568 million to third parties—a 16% decrease from 2022. The business also supplies APIs to Teva. The firm expects to complete the divestiture in the first half of 2025.
Aayushi Pratap (Mon,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: